The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIALS

Treatment of mitral regurgitation: cut, clip or medicate?

EuroIntervention 2019;14:1710-1712. DOI: 10.4244/EIJV14I17A294

1. New York Presbyterian Hospital, Columbia University Medical Center, The Cardiovascular Research Foundation, New York, NY, USA; 2. Baylor Scott & White Heart Hospital Plano, Plano, TX, USA


The different aetiologies of mitral regurgitation (MR) have a direct bearing on its prognostic impact and the selection and timing of treatment. Simply speaking, MR may be classified as degenerative (DMR) or functional (FMR), representing primary disease of the mitral valve (MV) or the left ventricle (LV), respectively. Surgical repair of severe DMR by experienced surgeons has high success rates with acceptable periprocedural morbidity and excellent durability, returning patients to their age/sex-matched expected survival. As such, surgical MV repair has a class I recommendation to treat severe DMR in the EU and US guidelines1,2, although with level of ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

What do MITRA-FR and COAPT teach us about the percutaneous treatment of secondary mitral regurgitation?